MEMBER PREVIEW
The action stops new-patient use and sales while authorities review concerns about the principal study behind the rare-disease medicine’s approval.
FREE MEMBER LOGIN
LOGIN TO CONTINUE READING.
Create or use your free IMG login to read standard articles. Important and Premium analysis also requires an active ₹99 or ₹199 plan.
The public preview and the member article share the same canonical page. No personalised investment recommendation is provided.